| Literature DB >> 23800279 |
Abstract
BACKGROUND: Histopathology has initially been and is still used to diagnose infectious, degenerative or neoplastic diseases in humans or animals. In addition to qualitative diagnoses semiquantitative scoring of a lesion`s magnitude on an ordinal scale is a commonly demanded task for histopathologists. Multiparametric, semiquantitative scoring systems for mouse models histopathology are a common approach to handle these questions and to include histopathologic information in biomedical research.Entities:
Mesh:
Year: 2013 PMID: 23800279 PMCID: PMC3693904 DOI: 10.1186/1746-6148-9-123
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Semiquantitative scoring systems for murine intestinal disease models
| DSS-induced [ | Proximal + middle + distal colon: crypt loss (0–4), inflammation (0–3) both quantified by the affected area (0–4) | 718 |
| DSS-induced [ | Extent, inflammation, necrosis, regeneration (each 3–0) | 321 |
| DSS-induced [ | Crypt damage, area involved, regeneration (each 0–4), extent (0–3), inflammation (0–3), | 255 |
| DSS-induced [ | Crypt loss (0–4), crypt distortion (0–4), epithelial hyperplasia (0–4), inflammation (0–3) each multiplied by percentage of involved area (0–4) | 185 |
| DSS-induced [ | Hyperplasia (0–3), severity (0–3), ulceration (0,1), area involved (0–4) | 147 |
| DSS-induced [ | Severity of inflammation, thickness of inflammation, epithelial damage character, extent of epithelial damage (each 0–3) | 130 |
| DSS-induced [ | Epithelium (goblet cell/crypt loss), infiltration (each 0–4) | 103 |
| DSS-induced [ | Infiltration, tissue damage (each 0–3) | 89 |
| TNBS-induced [ | Inflammation, loss of goblet cells, vascular density, transmural infiltration, thickening of the colon wall (together 0–4) | 788 |
| TNBS-induced [ | Crypt distortion, goblet cell loss, acute inflammation, chronic inflammation (each 0–2) | 126 |
| TNBS-induced [ | Loss of mucosal architecture, cellular infiltration, muscle thickening (each 0–3), crypt abscesses (0,1), goblet cell depletion (0,1) | 97 |
| Acetic acid-induced [ | Inflammation, bleeding, ulcer size, deepness, perforation (together 0–6) | 132 |
| TNBS-induced [ | Percentage of area, crypt loss (both 0–4) number of follicles, edema, erosion/ulceration, infiltration (each 0–3) | 57 |
| HLA-B27 transgenic mice [ | Inflammation, goblet cell loss, mucosal thickening, submucosal infiltration, architecture loss (each 0–4), ulcer, crypt abscess (each 0,1) | 423 |
| IL10-deficient mice [ | Mucosal ulceration, epithelial hyperplasia (both 0–3), Lamina propria mononuclear infiltrate, Lamina propria neutrophil infiltrate (each 0–2) | 423 |
| IL10-deficient mice [ | Inflammation/epithelial erosion/ulcers/hyperplasia/crypt abscesses/goblet cell depletion (together 0–4) multiplied by no. of affected colon segments (1–5) | 555 |
| MHC missmatch [ | Active inflammation (0.5-3), chronic inflammation (0.5-3), villous architecture (1–3) multiplied by the affected area (0.5-4) | 83 |
| Amebic colitis [ | Number of amoeba (0–5), ulceration (0-100%), inflammation (0–5) | 58 |
| Clostridial toxicosis [ | Epithelial damage, hyperemia/edema, neutrophils (each 0–3) | 202 |
| Intestinal ischemia [ | Normal mucosa (0), villous edema (1), subepithelial edema (2), epithelium loss at villi sides (3), denuded villi (4), loss of villous tissue (5), crypt infarction (6), transmucosal infarct (7), transmural infarct (8) | 270 |
| Intestinal ischemia [ | Mucosal damage, inflammation, hyperemia/hemorrhage (each 0–5) | 72 |
| Jejunitis [ | Villous length, villous tips, epithelium, inflammation, crypt loss (each 0–2), crypt abscesses, hemorrhage (each 0,1) | 15 |
| Bacterial ileitis [ | Hemorrhage, villous atrophy/necrosis, edema, congestion, neutrophils, epithelial necrosis (each 0–3) | 1 |
| Five areas multiplied by inflammation (0–3) | 49 | |
DSS, Dextran sodium sulfate; TNBS, 2,4,6-trinitrobenzene sulfonic acid, MHC, Major histocompatibility complex; HLA-B27, Human Leukocyte Antigen-B27, IL10, Interleukin 10.
Figure 1Flow chart visualizing the approach to identify 153 original, multiparametric, semiquantiative scoring systems by Pubmed data search.
Semiquantitative scoring systems for murine osteoarthritis models
| Arthritis [ | Cartilage structure (0–6), cells (0–3), Safranin-O-stain (0–4), tidemark integrity (0–1) | 1322 |
| Arthritis [ | Cartilage destruction (0–6), optional subgrading (subdivision in 2 subgrades) | 197 |
| Arthritis [ | Synovial lining, resident cell density, inflammation (each 0–3) | 49 |
| Collagen-induced [ | Extent of synovitis, cartilage loss, bone erosions (together 0–3) | 713 |
| Collagen-induced [ | Inflammation, cartilage destruction, bone erosion (each 0–3) | 273 |
| Collagen-induced [ | Infiltration in the exudate, infiltration of the synovial membrane, cartilage destruction, bone erosion (each 0–3) | 198 |
| Collagen-induced [ | Joint exudate (0–5), proteoglycan depletion (0–3) | 139 |
| Collagen-induced [ | Bone resorption, inflammation, cartilage damage (each 0–5) | 95 |
| Synovial thickening, infiltration, pannus formation (each 0–3) | 95 | |
| Adjuvant-induced [ | Percentage of affected area, synovial hyperplasia, cartilage destruction, bone erosion (each 0–3) | 64 |
| IL1-induced arthritis [ | Synovial infiltration, proteoglycan depletion, cartilage damage (each 0–3) | 41 |
| Instability-induced [ | Matrix structure, matrix staining, cellularity, subchondral bone (each 0–8) | 85 |
| Instability-induced [ | Cartilage destruction (0–4), osteophyte formation (0–3) | 85 |
| Hereditary arthritis [ | Articular cartilage structure (0–8), Toluidine blue-staining (0–6) | 52 |
| Bacterial arthritis [ | Infiltration (0–4), pannus formation, cartilage destruction, extra-articular manifestations, tail lesion (each 0,1) | 145 |
| Cartilage repair [ | Cell morphology (0–4), matrix staining (0–3), surface regularity (0–3), thickness (0–2), integration of donor cartilage (0–2) | 819 |
| Cartilage repair [ | Cellular morphology (0,2,4), Safranin-O stain (0–3), structural regularity (0–3), structural integrity (0–2), thickness (0–2), bonding (0–2), hypocellularity (0–3), chondrocyte clustering (0–2), adjacent degeneration (0–3) | 297 |
| Cartilage repair [ | Relative defect area (0–4), integration of repair tissue (0–3), matrix staining (0–4), cellular morphology (0–5), defect architecture (0–4), surface architecture, percentage of new bone (0–4), tidemark formation (0–4) | 222 |
| Cartilage repair [ | Filled depth (0–4), integration (0–2), surface architecture (0–3), cell morphology (0–3), cellularity (0–2), tidemark formation (0–4), Toloudin blue stain (0–2) | 130 |
| Cartilage repair [ | Defect filling (0–4), osteochondral reconstruction (0–2), matrix staining (0–4), cell morphology (0–4) | 96 |
IL1, Interleukin 1.
Semiquantitative scoring systems for murine renal disease models
| Lupus nephritis [ | Activity index (glomerular/tubulointerstitial abnormalities (6-tier, each 0–4)); chronicity index (4-tier, each 0–3) | 358 |
| Lupus nephritis [ | Mesangial thickening, extent of changes (together 0–4) | 44 |
| Lupus nephritis [ | Glomerular cell proliferation, lobulation, hyaline droplets, macrophage infiltration (together 0–3) | 25 |
| Lupus nephritis [ | Glomerular inflammation, proliferation, crescent formation, necrosis (each 0–3) | 1 |
| Toxic nephropathy [ | Glomerular cellularity, hypertrophy, thrombosis, dilation (together 0–5) | 4 |
| Toxic nephropathy [ | Glomerular injury, tubular cysts/casts, podocyte hyperplasia, interstitial inflammation (each 0–4) | 33 |
| Hypertension nephropathy [ | Mesangial matrix, percentage of glomerular affection (each 0–4) | 524 |
| Diabetic-/Hypertension-induced glomerulosclerosis [ | Arteriole hyalinization, glomerular sclerosis (0–4), interstitial volume (%) | 152 |
| Diabetic nephropathy [ | Glomerulosclerosis, interstitial fibrosis (each 0–4) | 15 |
| Crescentic glomerulonephritis[ | Fibrin deposition, immunoglobulin deposition, tubular damage, glomerular crescents (each 0–3) | 8 |
| MRL/MPJ mouse glomerulonephritis [ | Glomerular infiltration, crescents, necrosis, tubular casts, interstitial infiltrates (each 0–4) | 244 |
| Age-associated changes [ | Mesangial proliferation, sclerosis, hyalinization (together 0–5) | 27 |
| HIV-nephropathy [ | Tubuloepithelial degeneration/regeneration, tubular casts, dilation, interstitial infiltration, glomerular sclerosis, collapse, podocyte hyperplasia (each 0–3) | 47 |
| Obstructive nephropathy [ | Tubular dilation/atrophy, interstitial fibrosis (each 0–3) | 4 |
HIV, Human immunodeficiency virus; MRL, Murphy Roths Large.
Semiquantitative scoring systems for murine central nervous disease models
| Focal ischemia [ | Ischemic neuronal damage (0–3) | 2176 |
| Focal Ischemia[ | 18 areas x neuronal injury (0–5) | 23 |
| Global ischemia [ | Infarcts in 3 cerebral regions (0–4), hippocampus infarction (0–4) | 100 |
| Global ischemia [ | Eight regions x neuronal cell los/gliosis/iron deposition/gliosis (0–3) | 95 |
| Peripheral nerve ischemia [ | Edema, fiber regeneration (each 0–4) | 21 |
| EAE [ | Inflammation, neuronal degeneration (each 0–4) | 160 |
| EAE [ | Inflammation (cells/cuff), axonal injury, axonal loss (each 0–4) | 81 |
| EAE[ | Lesion severity, myelin loss/tissue injury, acute inflammation, chronic inflammation (each 0–5) | 79 |
| Theiler's murine encephalomyelitis virus [ | Neuropil inflammation, demyelination, necrosis, meningeal inflammation (each 0–4) | 77 |
| EAE [ | Infiltration, demyelination (together 0,1) in 16 regions | 64 |
| EAE [ | Inflammation, necrosis (each 0–3) | 53 |
| EAE [ | Inflammation (cuffs/100 m2), demyelination (lesions/mm2) | 52 |
| EAE [ | Meningitis (0–2), perivascular cuffing (0–5), demyelination (0–3) | 43 |
| EAE [ | Spinal cord demyelination (0–3), inflammatory cells (No./mm2) | 22 |
| SCT [ | Gray matter degeneration/infarction (0–4) in 5 μm serial sections | 33 |
| SCT [ | 150 μm intervals x Area affected by neuronal degeneration, malacia (0–4) | 23 |
| | | |
| Streptococcus meningitis [ | Meningeal inflammation (0–3) x four regions | 46 |
| Meningitis, perivascular cuffing, neuropil infiltration (each 0–4) | 41 | |
| Oxidative damage [ | 7 areas x necrosis (0–3) | 27 |
| Senescence [ | Spongiosis (0–3), lipofuscin positive cells (%) | 23 |
| Spinocerebellar ataxia [ | Molecular layer thickness, Purkinje cell loss (each 0–3) | 10 |
EAE, Experimental autoimmune encephalomyelitis, SCT, Spinal cord trauma, CNS, Central nervous system.
Semiquantitative scoring systems for murine models of pulmonary diseases
| Lung fibrosis [ | Alveolar/bronchial wall thickening, structure distortion, fibrosis (together 0–8) | 273 |
| Lung fibrosis [ | Fibroblastic foci, established fibrosis, intraalveolar macrophages (each 0–6) | 116 |
| Cystic fibrosis [ | Lymphoid infiltrate (0–5), goblet cell hyperplasia (0–2), mucus retention (0–3), bronchiolitis (0–5), pneumonia (0–3), edema (0–2) | 101 |
| Ventilator-induced lung injury [ | Alveolar congestion, hemorrhage, neutrophils in airspaces/vessel walls, alveolar wall thickness, hyaline membranes (each 0–4) | 78 |
| Pulmonary ischemia [ | Edema, inflammatory cell infiltration, vascular congestion, alveolar hemorrhage (each 0–3) | 5 |
| Smoke-induced pneumopathy [ | Alveolar emphysema, atelectasis, infiltration, hemorrhage, alveolar wall thickness, perivascular/peribronchiolar edema (each 0–3) | 4 |
| Lung inflammation [ | Perivascular edema (0–3), perivascular/-bronchiolar inflammation (0–3), goblet cell metaplasia (0–2) | 32 |
| Lung inflammation [ | Alvolear wall inflammation, perivenous regions, periarterial/peribronchial regions, venous/arterial endothelial lesion (each 0–3) | 30 |
| Acute lung inflammation [ | Alveolar necrosis, vascular congestion, infiltration by neutrophils/ macrophages (each 0–4) | 6 |
| RSV pneumonia [ | Peribronchiolitis, alveolitis, perivasculitis, hypertrophy of mucus-producing glands, eosinophilia (each 0–5). | 26 |
| Mycoplasma pneumonia [ | Quantity/quality of (peri-)bronchial infiltrates, bronchial luminal exudate, perivascular infiltrate, parenchymal pneumonia (0–3) | 56 |
| Cyst number (0–4), inflammation (0–5) | 87 | |
| Streptococcus pneumonia [ | Bronchitis, edema, interstitial inflammation, intraalveolar inflammation, pleuritis, endothelialitis (each 0–4) | 0 |
Semiquantitative scoring systems for cardiovascular and muscle disease models
| EMCV-induced myocarditis [ | Myocardial necrosis, infiltration, calcification, fibrosis (together 0–4) | 50 |
| Coxsackievirus-induced myocarditis [ | Myocardial necrosis, infiltration, calcification (together 0–4) | 33 |
| Coxsackievirus-induced myocarditis [ | Necrosis, inflammation, Evans blue-stain (each 0–4) | 17 |
| Dilated cardiomyopathy [ | Myocardial necrosis, fibrosis (together 0–4) | 20 |
| Chronic cardiotoxicity [ | Qualitative/quantitative myocardial degeneration score (each 0–4) | 72 |
| Aneurysm [ | Extent of medial, adventitial disruption/size of lesion (together 0–6) | 21 |
| Atherosclerosis [ | Medial erosion, foam cells, buried fibrous caps, chondrocyte-like cells, lateral xanthomas (each 0,1) | 2 |
| Vasculitis [ | Infiltration, elastic lamina destruction, intimal thickening (together 0–3) | 8 |
| Ischemic necrosis [ | Infiltration, necrosis, hemorrhage (together 0–10) | 14 |
| Trypanosoma myositis [ | Number of parasites, eosinophilic infiltration (each 0–3) | 0 |
EMCV, Encephalomyocarditis virus.
Semiquantitative scoring systems for murine hepatic and pancreatic disease models
| Chronic active hepatitis [ | Periportal bridging (0–10), intralobular necrosis, portal inflammation, fibrosis (each 0–4) | 2,609 |
| Chronic hepatitis [ | Periportal/septal inflammation (0–4), confluent necrosis (0–6), focal necrosis/apoptosis/inflammation (0–6), portal inflammation (0–4), fibrosis (0–6) | 2,001 |
| Chronic hepatitis [ | Mitotic activity, portal inflammation, ductular proliferation, councilman bodies, fibrosis (each 0–3) | 107 |
| Hepatic fibrosis [ | Centrolobular vein/perisinusoidal space fibrosis (each 0–2), portal tract fibrosis (0–3), septa number (0–3), septa width (0–5) | 135 |
| Acute hepatitis [ | Steatosis (0–4), necrosis, inflammation (each 0–2), | 218 |
| Acute hepatitis [ | Portal/lobular inflammation (each 0–3) | 41 |
| Nutritional hepatopathy [ | Hepatocyte degeneration, portal inflammation, portal fibrosis (each 0–3) | 25 |
| Alcohol-induced hepatopathy [ | Steatosis (%), inflammation/necrosis/fibrosis (each 0–2) | 8 |
| Non-alcoholic Steatohepatitis [ | Steatosis (0–3), hepatocellular ballooning (0–2), lobular inflammation (0–2) | 1,149 |
| Hepatic ischemia [ | Location, necrosis (together 0–4) | 12 |
| Acute pancreatits [ | Edema, necrosis, inflammation, hemorrhage, fat necrosis (each 0–4) | 307 |
| Acute pancreatitis [ | Edema, necrosis, inflammation, vacuolization (each 0–4) | 144 |
| Acute pancreatitis [ | Edema, necrosis, inflammation, hemorrhage (each 0–4) | 89 |
| Acute pancreatitis [ | Acinar-cell ghosts (%), acinar cells vacuolization/swelling (%) | 42 |
| Ischemia-induced acute pancreatitis [ | Edema, necrosis, infiltration, hemorrhage, vacuolization (each 0–3) | 14 |
| Autoimmune pancreatitis [ | Infiltration, necrosis, lipomatosis (0–4) | 42 |
| Insulitis [ | Islet infiltration, destruction, atrophy (0–5) | 49 |
Semiquantitative scoring systems for murine models of eye, skin and miscellaneous diseases
| Burn scars [ | Epidermal hyperplasia/hyperkeratosis, hair follicles, apocrine glands, smooth muscles, fibroplasia, vascular proliferation (each 0,1), collagen orientation (0–3) | 26 |
| Systemic sclerosis [ | Dermal inflammation, thickened collagen bundles, dermal thickness (each 0–3) | 18 |
| Atopic dermatitis [ | Epidermal hypertrophy, hyperkeratosis, parakeratosis, erosion, inflammation, edema, ulcer (each 0–4) | 8 |
| UV radiation-induced skin damage [ | Epidermal thickness (0–3), dermal cellularity (0–3), dermal cyst changes (0–5) | 7 |
| Epithelial irritation [ | Leukocyte infiltration (0–5), epithelial reaction (0,1) | 1 |
| Psoriasis [ | Munro abscesses (1.5), hyperkeratosis (0.5), parakeratosis (1), length of rete ridges (0.5–1.5), lack of granular layer (1), acanthosis (1), dermis lymphocytic infiltrate (0.5–1.5), papillary papillae congestion (1), thinning above papillae (0.5) | 18 |
| Psoriasis [ | Epidermal thickness, | 5 |
| Diabetic retinopathy [ | Inflammation (leukocytes/100 μm retina length), leukostasis (leukocytes per vessel lumen) | 25 |
| Oxygen induced retinopathy [ | Blood vessel growth, tufts, tortuosity, extraretinal neovascularization, vasoconstriction (each 0–3), hemorrhage (0,1) | 48 |
| Bacterial endophthalmitis [ | Inflammation, retinal architecture (each 0–4), | 18 |
| Autoimmune uveoretinitis [ | Infiltration (0–4) | 285 |
| Endotoxin uveitis [ | Inflammation (0–3) | 47 |
| Abdominal adhesion [ | Inflammation, fibrosis, necrosis/abscess, granulomas (each 0–3) | 100 |
| Abdominal adhesion [ | Vessel number, neutrophil infiltration, neutrophils at site (each 0–3) | 4 |
| Abdominal adhesion [ | Fibrotic matrix, collagen fibers, fibroblast proliferation (together 1–5) | n.r. |
| Embryonic development [ | Grading (0–5) of 17 parameters | 429 |
| Wound healing [ | Infiltration, granulation tissue, fibroblasts, collagen deposition (together 0–12) | 369 |
| Thyroiditis [ | Number of inflammatory foci, parenchymal destruction (together 0–4) | 77 |
| Vaginitis [ | Epithelial disruption, leucocyte infiltration, edema, vascular injection (each 0–4) | 74 |
| Esophagitis [ | Epithelial damage/hemorrhage (0–4), inflammation (0–3) | 6 |
| Lymph node [ | Heterophils, apoptotic histiocytes, sinus histiocytosis, follicular hyperplasia (together 0–5) | 1 |
| Spermatogenic activity [ | Presence of spermatozoa/spermatides/germ cells/sertoli cells (together 0–10) | n.r. |
n.r., not reported; UV, ultraviolet light.
Semiquantitative scoring systems for systemic disease models
| Intestinal acute GvHD [ | Small intestine: villous blunting, crypt regeneration/apoptosis/loss, enterocyte loss, infiltration (each 0–4); Colon: crypt regeneration, colonocyte vacuolization, crypt apoptosis/destruction, infiltration (each 0–4) | 389 |
| Acute GvHD [ | Small/large bowel: villous blunting, crypt regeneration/apoptosis/loss, luminal sloughing, infiltration, mucosal ulceration, epithelial/vacuolization (each 0–4), liver: portal infiltration, bile duct apoptosis/sloughing, parenchymal apoptosis/abscesses/mitoses, steatosis, cholestasis (each 0–4) | 170 |
| Acute GvHD [ | Skin: epidermal damage, dermal collagen density, dermal infiltration, subcutaneous fat loss, hair follicle loss (each 0–2), intestine: crypt apoptosis, inflammation(each 0–4), liver: bile duct injury (0–4) | 50 |
| Lung lesion [ | Alveolar membrane thickening, congestion, edema, intraalveolar hemorrhage, interstitial, intraalveolar infiltration (each 0–3) | 36 |
| Intestinal, pulmonary lesions [ | Intestine: % injury (number of edematous villi x 0,5 + number of villi with epithelial damage x 1), lung: number of neutrophils in 10 fields | 2 |
| Pulmonary, intestinal, renal, hepatic lesions [ | Lung: atelectasis, hemorrhage, edema, congestion, inflammation, hyp-eraeration (each 0–3); ileal mucosal damage, (0–5), liver: congestion, necrosis, vacuolization (each 0–3), Kidney: epithelial swelling, tubular dilation, necrosis, edema, microthrombosis (each 0–3) | 2 |
| [ | Complete assessment of all lymphoid organs (each 0–4) | 50 |
| Banff classification for renal rejection [ | Tubulitis, arteritis, mononuclear cell interstitial infiltrates, glomerulitis, interstitial fibrosis, tubular atrophy, glomerulopathy, mesangial matrix increase, vascular fibrous intimal thickening, arteriolar hyaline thickening (each 0–3) | 1.727 |
| Heart rejection 1990 [ | Infiltration, myocyte damage (0–4) | 1401 |
| Heart rejection 2005 [ | Infiltration, myocyte damage (0–3) | 365 |
| Lung rejection [ | Inflammation (0–4), lymphocyte infiltration (0–1), bronchiolitis obliterans (0–4), Vascular rejection (0–1), vasculitis (0–1) | 362 |
| Skin rejection [ | Acanthosis, ulceration, necrosis, inflammation, granulation tissue (0–5) | 1 |
GvHD, Graft versus host disease.